207_Combined course Presentations

Conclusions

 No significant differences were seen in efficacy between Cisplatin-Etoposide (CE) and Carboplatin-Paclitaxel (CP)

 There was no difference in pneumonitis or esophagitis rates between CE and CP. However, hematologic toxicities and N/V were significantly higher in the CE arm

 Both CE and CP with XRT are acceptable standards of care to treat stage III NSCLC, and prospective data is needed to determine the optimum regimen